Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

BRAFTOVI®Principal Display Panel (encorafenib)

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-02

DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT

NDC 70255-025-02

BRAFTOVI®
(encorafenib) capsules

75 mg

Rx only
90 Capsules

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-02

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Carton

DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT

NDC 70255-025-01

BRAFTOVI®
(encorafenib) capsules

75 mg

Rx only
2 Bottles x 90 Capsules

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Carton

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-06

DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT

NDC 70255-025-06

BRAFTOVI®
(encorafenib) capsules

75 mg

Rx only
60 Capsules

Sample–
Not For Sale

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-06

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-05

DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT

NDC 70255-025-05

BRAFTOVI®
(encorafenib) capsules

75 mg

Rx only
90 Capsules

Sample–
Not For Sale

PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label - 025-05
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event